Inhibition of Moloney murine lymphoma and sarcoma growth in vivo by dietary retinoids

Print
Published on Friday, 22 September 2017

Abstract

The effects of dietary retinoids on the growth of Moloney lymphoma (LSTRA) and sarcoma (MSC) in BALB/c mice were evaluated.

Transplantable syngeneic Moloney lymphoma and sarcoma tumors are immunogenic. Preimmunization with LSTRA cells provides protection against subsequent challenge and sarcomas spontaneously regress following injection of an appropriate inoculum of MSC cells.

In normal mice fed varying concentrations of all-trans-retinoic acid (RA) and given injections of 10(3) LSTRA cells, RA caused a dose-dependent increase in the number of survivors; 50% of the mice fed RA at 50 mg/kg of diet were long-term survivors. All animals died that were fed a control diet and challenged with 10(3) LSTRA cells. Athymic (nu/nu) mice fed RA were not protected against lymphoma growth, whereas euthymic (nu/+) mice were; therefore, the antitumor effect of RA was thymus dependent.

Primary immunization with irradiated LSTRA in the presence of RA caused a significant increase in cell-mediated cytotoxicity by spleen cells at 4 days after immunization. However, challenge of animals preimmunized with LSTRA in the presence of dietary RA revealed a dose-dependent inhibition of memory. A significant reduction in MSC growth was also observed in normal mice fed 13-cis-retinoic acid (cRA).

A comparison of the primary antilymphoma effect of dietary RA, cRA, N-(all-trans-retinoyl)-DL-leucine (RL), and N-(4-hydroxyphenyl)retinamide (4-HPR) revealed an efficacy hierarchy of RL greater than RA greater than cRA greater than 4-HPR with RL producing 70% long-term survivors at 115 days after challenge with 10(3) LSTRA cells.

These studies indicate that retinoids can inhibit the growth of transplantable, retroviral-induced, immunogenic tumors by thymus-dependent mechanisms and that a newly synthesized retinoylamino acid (RL) is more potent than RA at inhibiting Moloney lymphoma growth.

 

 

About this publication.

 

See also:

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives);

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- Cyclophosphamide plus Somatostatin, Bromocriptin, Retinoids, Melatonin and ACTH in the Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage: Results of a Phase II Trial;

- Relapse of High-Grade Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Melatonin, Retinoids, and ACTH;

- Low-grade Non-Hodgkin Lymphoma at Advanced Stage: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Retinoids, and Melatonin;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of Lymphomas;

- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report;

- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report;

- Congenital fibrosarcoma in complete remission with Somatostatin, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up.